Reduction of the nonspecific animal toxicity of anti-Tac(Fv)-PE38 by mutations in the framework regions of the Fv which lower the isoelectric point

Journal of Immunology

Volumn 163, Issue 11, 1999, Pages 6072-6077

  Onda, Masanori ^a   Kreitman, Robert J ^a   Vasmatzis, George ^a   Lee, Byungkook ^a   Pastan, Ira ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; IMMUNOTOXIN; IMMUNOTOXIN LMB2; INTERLEUKIN 2 RECEPTOR ANTIBODY; PSEUDOMONAS EXOTOXIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIBODY STRUCTURE; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CYTOTOXICITY; DOSE RESPONSE; FEMALE; IMMUNOTOXICITY; INTRAVENOUS DRUG ADMINISTRATION; ISOELECTRIC POINT; MALE; MOLECULAR MODEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS;

ADP RIBOSE TRANSFERASES; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; BACTERIAL TOXINS; DOSE-RESPONSE RELATIONSHIP, DRUG; EXOTOXINS; FEMALE; IMMUNOGLOBULIN FRAGMENTS; IMMUNOTOXINS; ISOELECTRIC POINT; LIVER; MICE; MICE, NUDE; MUTATION; NEOPLASMS, EXPERIMENTAL; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; TOXICITY TESTS; VIRULENCE FACTORS;

EID: 0033485916     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Kreitman, R. J., and I. Pastan. 1998. Immunotoxins for targeted therapy. Adv. Drug Delivery Rev. 31:53.
2. Chaudhary, V. K., C. Queen, R. P. Junghans, T. A. Waldmann, D. J. FitzGerald, and I. Pastan. 1989. A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin. Nature 339:394.
3. Siegall, C. B., V. K. Chaudhary, D. J. FitzGerald, and I. Pastan. 1989. Functional analysis of domains II, Ib and III of Pseudomonas exotoxin. J. Biol. Chem. 264:14256.
4. Brinkmann, U., and I. Pastan. 1994. Immunotoxins against cancer. Biochim. Biophys. Acta 1198:27.
5. Reiter, Y., and I. Pastan. 1998. Recombinant Fv immunotoxins and Fv fragments as novel agents for cancer therapy and diagnosis. Trends Biotechnol. 16:513.
6. Kreitman, R. J., and I. Pastan. 1995. Targeting Pseudomonas exotoxin to hematologic malignancies. Semin. Cancer Biol. 6:297.
7. Kreitman, R. J., Q. C. Wang, D. J. P. FitzGerald, and I. Pastan. 1999. Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)PE38 at doses tolerated by cynomolgus monkeys. Int. J. Cancer 81:148.
8. Kunkel, T. A., K. Bebenek, and J. McClary. 1991. Efficient site-directed mutagenesis using uracil-containing DNA. Methods Enzymol. 204:125.
9. Chowdhury, P. S., J. L. Viner, R. Beers, and I. Pastan. 1998. Isolation of a high affinity stable single chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity. Proc. Natl. Acad. Sci. USA 95:669.
10. Kreitman, R. J., C. B. Siegall, D. J. P. FitzGerald, J. Epstein, B. Barlogie, and I. Pastan. 1992. Interleukin 6 fused to a mutant form of Pseudomonas exotoxin kills malignant cells from patients with multiple myeloma. Blood 80:2344.
11. Kreitman, R. J., P. Bailon, V. K. Chaudhary, D. J. P. FitzGerald, and I. Pastan. 1994. Recombinant immunotoxins containing anti-Tac(Fv) and derivatives of Pseudomonas exotoxin produce complete regression in mice of an interleukin-2 receptor-expressing human carcinoma. Blood 83:426.
12. Kabat, E. A., T. T. Wu, H. M. Perry, K. S. Gottesman, and C. Foeller. 1991. Sequence of Proteins of Immunological Interest. U.S. Department of Health and Human Services, Washington, DC, Publ. no. 1-1-1137.
13. Chowdhury, P. S., G. Vasmatzis, B. Lee., and I. Pastan. 1998. Improved stability and yield of a Fv-toxin fusion protein by computer design and protein engineering of the Fv. J. Mol. Biol. 281:917.
14. Pardridge, W. M., J. Buciak, J. Yang, and D. Wu. 1998. Enhanced endocytosis in cultured human breast carcinoma cells and in vivo biodistribution in rats of a humanized monoclonal antibody after cationization of the protein. J. Pharmacol. Exp. Ther. 286:548.
15. Pardridge, W. M., Y. S. Kang, J. Yang, and J. L. Buciak. 1995. Enhanced cellular uptake and in vivo biodistribution of a monoclonal antibody following cationization. J. Pharm. Sci. 84:943.
16. Pardridge, W. M., Y. S. Kang, A. Diagne, and J. A. Zack. 1996. Cationized hyperimmune immunoglobulins: pharmacokinetics, toxicity evaluation and treatment of human immunodeficiency virus-infected human-peripheral blood lymphocytes-severe combined immune deficiency mice. J. Pharmacol. Exp. Ther. 276:246.
17. Soler-Rodriguez, A.-M., M.-A. Ghetie, N. Oppenheimer-Marks, J. W. Uhr, and E. S. Vitetta. 1993. Ricin α-chain and ricin α-chain immunotoxins rapidly damage human endothelial cells: implications for vascular leak syndrome. Exp. Cell Res. 206:227.
18. Y damage endothelial cells in an antibody specific mode: relevance to vascular leak syndrome. Clin. Cancer Res. 1:1589.
19. Nicholls, A., K. Sharp, and B. Honig. 1991. Protein folding and association: insights from the interfacial and thermodymanic properties of hycrocarbons. Proteins Struct. Funct. Genet. 11:281.
20. Carson, M. 1991. Ribbons 2.0. J. Appl. Crystallogr. 24:958.
21. Rudikoff, S., Y. Satow, E. Padlan, D. Davies, and M. Potter. 1981. κ-Chain structure from a crystallized murine Fab': role of joining segment in hapten binding. Mol. Immunol. 18:705.
22. Kreitman, R. J., Wilson, D. Robbins, I. Margulies, M. Stetler-Stevenson, T. Walmann, and I. Pastan. 1999. Responses in refactory hairy cell leukemia to a recombinant immunotoxin. Blood, In press.